Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Biologics/DMARDs

Investigational Nanobody Compound Shows Promise for RA Treatment

Michele B. Kaufman, PharmD, BCGP  |  September 14, 2023

In Japan, ozoralizumab will soon be available as a 30 mg subcutaneous auto-injection to treat patients with rheumatoid arthritis.

A Novel Study Compared the Effectiveness of Adalimumab with Tofacitinib in RA

Samantha C. Shapiro, MD  |  August 17, 2023

Your patient with rheumatoid arthritis (RA) isn’t responding well enough to methotrexate, and you both agree it’s time to consider a biologic or targeted synthetic disease-modifying anti-rheumatic drug (DMARD). But which one should you choose? In a treat-to-target era, we’re fortunate to have a variety of RA therapies at our disposal. Clinical practice guidelines from…

Do NSAIDs Mask MRI Findings in Patients with Axial Spondyloarthritis?

Michele B. Kaufman, PharmD, BCGP  |  July 17, 2023

Research suggests the use of non-steroidal anti-inflammatory drugs may mask the amount of sacroiliac joint inflammation found on MRI in patients with axial spondyloarthritis.

A Dual Inhibitor Treatment for RA?

Michele B. Kaufman, PharmD, BCGP  |  July 17, 2023

TLL-018, a Janus kinase 1/tyrosine kinase 2 inhibitor, proved more effective for treating patients with RA than tofacitinib, according to a study by Zeng et al.

Many Medications: Understanding the Biologic Management of Psoriasis

Jason Liebowitz, MD, FACR  |  June 15, 2023

ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.

First Biosimilar to Adalimumab (Humira) Enters the U.S. Market After Years of Legal Battles

Michele B. Kaufman, PharmD, BCGP  |  January 31, 2023

After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.

Rheumatology Medications with Limited Safety Data: How Do We Use Them in Pregnant Patients?

Samantha C. Shapiro, MD  |  December 6, 2022

How does a rheumatologist treat a pregnant woman when many medications are not approved for pregnancy or safety data are limited?

Ongoing Advocacy Efforts Seek Use of Complex Administration Codes for Biologics

From the College  |  August 8, 2022

Ongoing ACR advocacy efforts are working to keep biologic drugs accessible to rheumatology patients, defending the ability of rheumatology practices to use the complex chemotherapy codes for administration of biologic therapies.

Biologic or Conventional Therapy for Early RA?

Michele B. Kaufman, PharmD, BCGP  |  July 19, 2022

A study has shown that in untreated patients with early RA, treatment with methotrexate combined with the biologic therapies abatacept or certolizumab-pegol resulted in greater CDAI remission rates than active conventional therapy with prednisolone, sulfasalazine or hydroxychloroquine.

FDA Approves Riabni, a Rituxumab Biosimilar, to Treat Patients with RA

Michele B. Kaufman, PharmD, BCGP  |  July 13, 2022

Based on findings from a double-blind, placebo-controlled study evaluating its efficacy and safety, rituximab-arrx has received FDA approval for the treatment of patients with rheumatoid arthritis.

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences